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mice showed signs of kidney insufficiency, demonstrated by enhanced serum creatinine levels, quite similar to COX-2 Ϫ/Ϫ mice, but, in contrast, serum urea remained at the control level. In summary, function of both COX-2 gene alleles is absolutely necessary to ensure physiological development of the mouse kidney. Loss of one copy of the COX-2 gene or partial COX-2 inhibition is associated with distinct renal damage and reduced kidney function.
prostaglandins; cyclooxygenase-2; nephrogenesis; kidney development CYCLOOXYGENASE (COX) is a key enzyme of the arachidonic acid metabolism leading to various bioactive prostanoids, e.g., PGE 2 . Two isoforms of COX are known: COX-1 and COX-2, which are both expressed in the adult kidney and, most likely, linked to different responsibilities for renal prostanoid synthesis. In adult mice, COX-1 is highly expressed in the collecting duct, and low levels of COX-1 have been detected in interstitial cells, glomerular mesangial cells, and endothelial cells of arterioles (5) . It appears to provide prostanoids involved in the modulation of tubular salt and water reabsorption (for a review, see Ref. 17) . COX-2, on the other hand, is expressed predominantly in renal medullary interstitial cells, cortical thick ascending limbs, and cells associated with the macula densa (16, 18, 19) . As increased macula densa COX-2 expression has been linked to high renin levels in rodents (19) and humans (22) , it has been suggested that prostanoids involved in macula densa-dependent secretion of renin are supplied by COX-2. In mice, gene deletion of COX-2 leads to defects in kidney development, demonstrated by the appearance of hypoplastic glomeruli and cyst formation in multiple nephron segments, a thinned cortical area, an abnormal accumulation of superficial immature glomeruli, and poor tubule differentiation within the thin nephrogenic cortex (12, 27) . These morphological changes are thought to be responsible for kidney insufficiency in COX-2 Ϫ/Ϫ mice, exhibited by elevated serum creatinine and urea levels, and are believed to cause renal failure in adult mice (29) . The mechanisms behind these pathological alterations are unknown. It is assumed that specific lack of COX-2-dependent prostanoid synthesis and therefore nontriggered downstream signal transduction mechanisms are involved (15) , as COX-1 is not able to compensate for the deficiency. Mice lacking COX-1 have no discernible kidney phenotype or renal functional alteration (25) . Whether one allele in heterozygous COX-2 knockout mice is sufficient for compensation is unknown. Application of COX-unselective inhibitors such as diclofenac or COX-2-selective inhibitors such as rofecoxib at dosages suppressing Ͼ90% of COX-2 activity causes similar histological defects in the kidney as seen in knockout mice (30) . In hypomorphic COX-2 Neo/Neo mice in which COX-2 expression was reduced 70 -90%, a mild renal phenotype with minimal signs of renal dysfunction has been reported (32) . Importantly, in humans, in utero exposure to COX inhibitors is also associated with renohistological defects such as small glomeruli, incomplete tubular differentiation, and cortical growth and can cause impairment of renal functions, e.g., oligohydramnion due to reduced fetal urine production and renal failure in the neonate (21, 34) . It is unknown whether complete inhibition is necessary or if partial inhibition of COX-2 activity is sufficient to impair renal development.
Nephrogenesis in the mouse kidney (Mus musculus) begins at embryonic day (E)10.5 and ends ϳ10 -14 days postpartum (31a, 33) . During this period, new nephrons are continually being generated from the nephrogenic mesenchyme in response to signals emanating from the tips of the branching ureter (10) . The kidney continues to develop from the center toward the periphery. As a result, the oldest and most mature nephrons are located in the inner cortex and the least mature nephrons are located in the outer cortex. In mice, pharmacological inhibition of COX-2 activity limited to the postnatal time course impairs nephrogenesis, whereas inhibition limited to the gestational period does not affect kidney development (23) . Furthermore, kidneys from E14 COX-2 Ϫ/Ϫ fetuses appeared normal (12) . These findings indicate that, in mice, the COX-2 pathway plays a role in nephrogenesis after birth. The postnatal timeframe most sensitive to COX-2 inhibition-induced renal injury in mice was identified between postnatal day (P)4 and P8. This timeframe overlaps with a transient rise in the renal expression of COX-2 (15, 23) and membrane-associated PGE synthase (mPGES)-1 (15) and enhanced PGE 2 synthetic capacity is detectable (15) . The importance of the COX-2/mPGES-1/PGE 2 axis for normal renal development is supported by the observation that mice deficient in the PGE 2 receptors EP2 and EP4 also show defects in nephrogenesis quite similar to COX-2 inhibition or deletion, albeit not to the same extent (15) . However, the contribution of other prostanoids, e.g., PGI 2 , to COX-2-conducted nephrogenesis cannot be excluded.
In the human population, polymorphisms have been described that affect COX-2 expression, but the consequences on COX-2 activity are still unclear. These gene alterations have been mainly studied within the context of cancer risk (9) or stroke (8) . It is unknown whether partial gene alterations, e.g., by polymorphisms or mutation, lead to reduced renal COX-2 activity and impaired kidney development. We hypothesized that the number of functional alleles for COX-2 affects the degree of COX-2 activity and that the number is important for normal kidney development and function. Furthermore, we predicted that partial pharmacological inhibition of COX-2 would cause some degree of kidney damage. To clarify this, we studied postnatal nephrogenesis in mice homozygous and heterozygous for COX-2 in relation to dose-dependent inhibition of COX-2.
MATERIALS AND METHODS

Animals and treatment.
All animal care and experimental procedures were in accordance with institutional guidelines and approved by the Animal Welfare Committee of the State Agency Darmstadt (Germany). Breeder pairs of wild-type C57/BL6J mice were obtained from Jackson Laboratories (Bar Harbour, ME). Breeder pairs of COX-2 ϩ/Ϫ mice were kindly provided by Robert Langenbach (National Institute of Environmental Health Sciences) (27) and were backcrossed to C57/BL6J mice for Ͼ10 generations. COX-2 ϩ/ϩ , heterozygous COX-2 ϩ/Ϫ , and homozygous COX-2 Ϫ/Ϫ littermates of each sex were used in the study. Genotypes of the mice were determined by PCR analysis using specific oligonucleotides to the respective COX-2 locus and the Neo cassette. Animals were maintained in individually ventilated cages in a temperature-controlled (21°C) room with a 12:12-h light-dark cycle. Mice were fed normal mouse chow. All animals had free access to food and water. The day of birth was defined P0. The selective COX-2 inhibitor SC-236, which exhibits a COX-2/COX-1 selectivity of 1,780 (31), was purchased from Sigma-Aldrich (St. Louis, MO). To study the effect of COX-2 inhibition on nephrogenesis, treatments with SC-236 (injected subcutaneously between the shoulder blades of the pups once a day) were started on P1. The control group received DMSO as a vehicle. The injected volume was adjusted roughly to body weight, so that from P1 to P6 SC-236 was dissolved in DMSO in a volume of 5 l and from P7 to P10 in a volume of 7.5 l. Treatment continued until P7 if the animals were euthanized on P8 or until P10 if harvesting took place on P21.
Measurement of blood and urine parameters. Hematocrit and plasma electrolytes were determined in mice at the age of P8 using a blood gas analyzer (GEM Premier 4000, Werfen, Kirchheim, Germany) and whole blood samples. Concentrations of urea and creatinine were determined by laboratory analysis (Laboklin, Bad Kissingen, Germany) in serum samples from mice at age P90 to study the long-term effects of COX-2 gene deletion on renal function. To estimate food and water intake, urine volume, and Na ϩ and albumin excretion, mice at ages of P70 -P90 were weighed and housed in metabolism cages, and urine was collected on ice. Urinary albumin was determined by ELISA (ICL, Portland, OR) and Na ϩ in urine samples by laboratory analysis (Laboklin).
Tissue preparation and micrography. After anesthesia with ketamine-xylazine, mice were weighed and euthanized by cardiac puncture at P21 after weaning. Kidneys were immediately removed, weighed, sagitally hemisected, and immersion fixed overnight in 4% paraformaldehyde-PBS as previously described (22, 29, 30) . Kidney tissue was embedded in paraffin, and sections were cut at a thickness of 4 m, dewaxed in xylene, and stained with hematoxyline and eosin. Renal histomorphometric analysis, with the determination of the mean diameter of glomeruli, subcapsular cortical thickness, and relative amount of superficial glomeruli, was done as previously described (30) . Three kidney sections at least 50 -60 m apart from 6 -13 animals (as indicated) from each group were selected. Photomicrographs were obtained using Axioskop (Carl Zeiss MicroImaging, Göttingen, Germany) provided with the AxioCam digital camera and software, and a total of ϳ200 glomeruli/animal chosen at random from the superficial cortex, midcortex, and juxtamedullary region were digitized for each group. Analysis was performed by two operators unaware of the origin of each kidney section. The crosssectional diameter of glomeruli and the distances from the kidney edge to Bowman's capsule were measured perpendicularly to the renal capsule using ImageJ software (National Institutes of Health). Glomeruli that appeared to be cut tangentially were excluded from the observation group. Subcortical thickness (cortex corticis) was determined by the distance from the nearest glomeruli to the cortical edge as previously described (15, 30) . To account for the relative amount of superficial glomeruli, we set a distance limit of 70.34 m from the cortical edge, defined by the sum of the distance of glomeruli located nearest to the surface plus one mean diameter of glomeruli in control kidneys (15, 30) . In addition, diameters of juxtamedullary glomeruli located close to the medullary border were recorded separately. To determine the size of juxtamedullary glomeruli, the 10 glomeruli located closest to the medulla in each mouse were used for calculation.
Quantitative real-time PCR. Kidneys from mice were dissected at P8 and stored at Ϫ80°C until analysis. Total RNA was isolated using the peqGold kit (Peqlab Biotechnologie, Erlangen, Germany) according to the manufacturer's instructions. The RNA concentration was quantified by absorbance at a wavelength of 260 nm using a NanoDrop spectrophotometer (Peqlab Biotechnologie). RNA (0.8 g) was reverse transcribed using a first-strand cDNA synthesis kit and random hexamers (Thermo Fisher Scientific) in 20 l, and 1 l of a 1:4 dilution of the resulting cDNA samples was used as a template for real-time PCR using the SYBR green supermix reaction procedure with a 7500 Fast System (Applied Biosystems, Darmstadt, Germany). All reactions were run in triplicate to minimize experimental error. The following primer pairs were used: for COX-2, 5=-AAGAC-TACGTGCAACACCTGAG-3= and 5=-GTGCCAGTGATAGAGT-GTGT-3=; for mPGES-1, 5=-ACAGGCCAGATGAGGCTGCG-GAA-3= and 5=-TCTCCATGTCGTTGCGGTGGGCT-3=; for prostacyclin synthase (PGIS), 5=-ACAGCATCAAACAATTTGTCGTC-3= and 5=-GCATCAGACCGAAGCCATATCT-3=; and for GAPDH, 5=-CAATGTGTCCGTCGTGGATCT-3= and 5=-GTCCTCAGTG-TAGCCCAAGAT-3=. PCR was initiated at 95°C for 15 min followed by 40 cycles of 15 s at 95°C and 1 min at 60°C for annealing and extension. The expression of mRNA was assessed relative to that of GAPDH, and the relative quantitative level of samples (from 6 mice) was determined by the standard 2
Ϫ⌬⌬Ct method (where Ct is threshold cycle) and expressed as change (fold) relative to expression levels in COX-2 ϩ/ϩ mice. Assay for PGE2 and PGI2 synthetic activity. For the determination of PGE2 and PGI2 synthesis, kidneys from P8 mice were weighed and rapidly homogenized in 4 volumes (wt/vol) of cold tissue buffer [50 mM Tris (pH7.4), 1 mM phenol, and 1ϫ protease inhibitor cocktail set (Merck Chemicals, Darmstadt, Germany)] with a Potter Elvehjem homogenizer followed by ultrasonification (5-10 times for 2-4 s).
Homogenates were centrifuged for 10 min at 3,000 g and 4°C, and the protein concentration of the supernatants was determined. Samples of 100 g protein were prewarmed at 37°C for 1 min, and reactions were started by the addition of 50 M arachidonic acid. After 10 min of incubation, the reaction was stopped with 1% formic acid. PGE2 and 6-keto-PGF 1␣, the stable hydrolyzation product of PGI2, were extracted and determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Incubation in the presence of 10 M indomethacin served as a control for COX-dependent prostanoid synthesis (data not shown). For liquid-liquid extraction, samples were incubated with extraction buffer containing 600 l of ethyl acetate, 100 l of 150 mM EDTA, and 20 l of internal standard solution (25 ng/ml of [ 2 H4]-PGE2 or [
2 H4]-6-keto-PGF1␣ in methanol). Samples were homogenized using Mixer Mill MM400 (Retsch, Haan, Germany) and centrifuged at 20,000 g for 150 s. The extraction was repeated, and extraction solvents were removed at 45°C under a gentle stream of nitrogen and stored at Ϫ80°C until measurement. The residues were reconstituted with 50 l of acetonitrile-water-formic acid [20:80: 0.0025 (vol/vol), pH 4.0] and injected into the LC-MS/MS. PGE2 or 6-keto-PGF 1␣ was separated with a Synergi 150 ϫ 2.0-mm Hydro-RP column (Phenomenex, Aschaffenburg, Germany) and determined with a triple quadrupole mass spectrometer (5500 Q-TRAP Sciex, Darmstadt, Germany) (4) .
Determination of relative expression of COX-2 by ELISA. Whole kidneys prepared on P8 were homogenized in cold solubilization buffer [PBS (pH7.4), 10% glycerol, 1% Triton X-100, 1ϫ protease inhibitor cocktail set III (Merck Chemicals), and 0.02% Tween 20] using mixer mill MM400 (Retsch) at 20 Hz for 2 min. Thereafter, samples were centrifuged at 4°C and 20,000 g for 20 min. The resulting supernatant was used for analysis. ELISA plates (96 wells) were coated overnight with mouse monoclonal capture antibody (200 ng/well) to COX-2 (reacting with mouse and human COX-2, Abcam, Cambridge, UK) diluted in 100 mM carbonate buffer (pH 9.6). Antibody was removed, and plates were washed with PBS and 0.1% Tween 20 (PBST; pH 7.4). Plates were blocked overnight with blocking reagent (Pierce protein-free T20, Thermo Scientific) at 4°C. Blocking buffer was removed, and solubilized kidney samples were added and incubated at 4°C overnight. Sample solution was removed, plates were washed three times with PBST, and avidin-biotin blocking solution (Vector) was added for 10 min. After a wash with PBST, polyclonal rabbit anti mouse COX-2 antibody (reacting with mouse, rat, and human COX-2, Abcam), used as a detector antibody and diluted in blocking buffer, was added and incubated at 4°C overnight. After a wash with PBST, aliquots of biotinylated goat anti-rabbit antibody (Vector) were added and incubated for 1 h at room temperature. Plates were washed three times with PBST, and horseradish peroxidase-conjugated avidin (Vector) was added for 1 h at room temperature. After four wash steps with PBST, plates were incubated with TMB substrate solution (Thermo Scientific) for 15 min and stopped by the addition of 2 M sulfuric acid. Absorbance of each well was measured at 450 nm. Solubilized kidney tissue from COX-2 Ϫ/Ϫ mice was used to subtract background absorbance. No significant absorbance was observed using commercial COX-1 transfected 293T lysate (Santa Cruz, Heidelberg, Germany) as a sample. The intraassay variation was ϳ8%, the interassay variation was 13%, and the relative range was 3-4 twofold dilutions. Data are presented as relative amounts compared with the control.
PGE2 excretion rate. C57/BL6 mice at the age of 12 wk were treated for 10 days with the COX-2-selective inhibitor SC-236 at 5 and 10 mg·kg Ϫ1 ·day Ϫ1 or with vehicle. SC-236 was dissolved in DMSO and injected intraperitoneally once a day. On the last day of substance application, mice were placed in metabolism cages for 4 h, and urine was collected on ice. After centrifugation, urine volume was removed and determined by weighing, and the PGE2 concentration in urine samples was determined by an EIA assay (BioMol, Hamburg, Germany).
Histochemistry. The organs were routinely fixed in 4% neutral buffered formalin and embedded in paraffin. Sections were cut with a microtome (4 m thick), deparaffinized, and subjected to Sirius red staining (Science Services, Munich, Germany) to evaluate periglomerular fibrosis and glomerulosclerosis, respectively, defined by the presence of increased amounts of Sirius red-positive material within Bowman's capsule and the glomerulus, respectively (30) . For each group, 12-17 glomeruli were chosen randomly and digitally imaged. Glomeruli that appeared to be cut tangentially were excluded from the observation group. The glomerular tuft and periglomerular Bowman's capsule, respectively, were digitally excised, and quantitative analysis of the pictures was performed using Adobe Photoshop CS6 software and ImageJ software, which allows for the quantification of the stained pixels. The results are given as stained pixels per area of the outer membrane of Bowman's capsule and the glomerular tuft, respectively. All tissue samples were evaluated independently by two investigators without prior knowledge of the group to which the mice belonged.
Statistics. Data are presented as means Ϯ SE. Analysis were performed by ANOVA and a post hoc Tukey multiple-comparison test for all groups or a post hoc Dunnett multiple-comparison test to compare against the control group. Two-group comparisons were done by a t-test. Prism 6.0 software (Graphpad) was used for all calculations. The probability value for significance was defined as P Ͻ 0.05.
RESULTS
The ratio of kidney to body weight revealed that kidney growth was significantly diminished in COX-2 Ϫ/Ϫ mice, whereas no significant differences were observed in heterozygous mice compared with COX-2 ϩ/ϩ mice. No differences were seen between the three genotypes of COX-2 regarding plasma Na ϩ , K ϩ , and Ca 2ϩ concentrations. In COX-2 ϩ/Ϫ and COX-2 Ϫ/Ϫ mice, plasma Cl Ϫ concentration was significantly reduced (102.6 Ϯ 0.8 vs. 99.6 Ϯ 0.5 mM, P Ͻ 0.05, and vs. 99.5 Ϯ 0.8 mM, P Ͻ 0.05), and hematocrit was increased only in COX-2 Ϫ/Ϫ mice (18.88 Ϯ 1.24% vs. 27.43 Ϯ 4.60%, P Ͻ 0.05). Compared with COX-2 ϩ/ϩ mice, no differences were observed in food and water intake, daily urine output, and Na Table 1) .
Impairment of nephrogenesis. In control COX-2 ϩ/ϩ mice at P21, glomeruli exhibited a mature morphology with minimal space between the glomerular tuft and Bowman's capsule and several layers of tubules occupying the space between the renal capsule and subcapsular glomeruli, the cortex corticis (Fig. 1) . In COX-2 Ϫ/Ϫ mice, glomeruli exhibited a reduced size, condensed glomerular tuft partially with increased urinary space of Bowman's capsule, and strongly reduced thickness of subcapsular cortical tissue. The morphological structure in COX-2 ϩ/Ϫ mice represents an intermediate state between COX-2 ϩ/ϩ and COX-2 Ϫ/Ϫ mice with a reduced glomerular size, condensed glomerular tuft, and thinning of the outer cortical edge (Fig. 1) . The alterations appeared to be less severe than in COX-2
Histomorphological analysis of kidneys derived from the different COX-2 genotypes at P21 revealed that the diameters of glomeruli were significantly reduced in COX-2 Ϫ/Ϫ com-pared with COX-2 ϩ/ϩ kidneys (32.00 Ϯ 1.39 vs. 46.10 Ϯ 0.51 m, P Ͻ 0.001) but also in COX-2 ϩ/Ϫ compared with control kidneys (37.79 Ϯ 1.09 vs. 45.75 Ϯ 0.52 m, P Ͻ 0.001; Fig.  2A ). Regarding the distance of superficial glomeruli to the cortical edge, which gives an estimation of the subscapsular cortical growth (30) , kidneys from heterozygous mice showed a slight but significant difference compared with COX-2 ϩ/ϩ mice (41.01 Ϯ 2.20 vs. 48.37 Ϯ 1.24 m, P Ͻ 0.05), whereas null mice exerted strong cortical thinning (15.41 Ϯ 1.66 m, P Ͻ 0.001; Fig. 2B ). However, the relative amount of superficial glomeruli, which gives a measure for maturational arrest of newly formed nephrons in the outer cortex (30), did not differ in the COX-2 ϩ/Ϫ group compared with the control group. Typically, COX-2 Ϫ/Ϫ mice showed a strong increase in superficially located small glomeruli (Fig. 2C) . Subgroup analysis of juxtamedullary glomeruli, which are developed in the early stages of nephrogenesis (20), also revealed a significant size reduction in kidneys from COX-2 ϩ/Ϫ mice, which was more pronounced in COX-2 Ϫ/Ϫ mice (49.83 Ϯ 3.32 m, P Ͻ 0.05, and 46.69 Ϯ 2.25 vs. 59.07 Ϯ 2.40 m, P Ͻ 0.01; Fig. 2D ). Values are means Ϯ SE; n, number of mice/group. COX, cyclooxygenase. *P Ͻ 0.05 by ANOVA with post hoc Dunnettś multiple-comparison test compared with COX-2 ϩ/ϩ mice. . In COX-2 ϩ/ϩ mice, glomeruli exhibited a mature morphology (exemplarily indicated by the small arrow) with normal growth of subcapsular glomeruli-free cortical tissue (indicated by the thick arrow). In COX-2 Ϫ/Ϫ mice, glomeruli exhibited reduced size (exemplarily indicated by the small arrow) and the subcapsular cortical tissue was strongly thinned (indicated by the thick arrow). The morphological structure of COX-2 ϩ/Ϫ glomeruli appeared to be in between COX-2 ϩ/ϩ and COX-2 Ϫ/Ϫ with moderate reduced glomerular size and condensed glomerular tuft as well as a slight reduction in cortical thickness.
To clarify whether a different number of COX-2 alleles may also affect COX-2 enzyme function, we determined relative mRNA and protein levels of COX-2 as well as COX synthetic activity in mouse kidneys at the age of P8, the critical time point in nephrogenesis for the presence of COX-2 (15) . Semiquantitative PCR analysis demonstrated that in COX-2 ϩ/Ϫ mice, the amount of COX-2 mRNA was significantly reduced compared with COX-2 ϩ/ϩ mice (Fig. 3A) . No significant signal was detected in COX-2-null mice (data not shown). This observation was paralleled at the protein level, with a reduced relative amount of COX-2 protein in kidneys from COX-2 ϩ/Ϫ mice (Fig. 3B) . Analysis of the mRNA expression of mPGES-1 revealed a significantly higher expression in COX-2 ϩ/Ϫ and COX-2 Ϫ/Ϫ kidneys and for PGIS in COX-2 Ϫ/Ϫ kidneys (Fig.  3, C and D) . Interestingly, the capacity of kidney homogenates to metabolize exogenously added arachidonic acid to PGE 2 or to PGI 2 , determined by its stable hydrolyzation product 6-keto-PGF 1␣ , was reduced in COX-2 heterozygous mice (P Ͻ 0.05) and more strongly in COX-2-null mice (P Ͻ 0.005 for PGE 2 synthesis and P Ͻ 0.001 for PGI 2 synthesis; Fig. 3E ). As expected, prostanoid synthetic capacity could be blocked nearly completely by the COX-unselective inhibitor indomethacin (data not shown), excluding appreciable nonenzymatic formation of PGE 2 or 6-keto-PGF 1␣ in our assay.
In the next set of experiments, we studied the effect of high and low dosages of the COX-2-selective inhibitor SC-236 on renal morphology. SC-236 was administrated to wild-type C57/BL6 mice from P1 to P10. SC-236 given at 10 mg·kg Ϫ1 ·day Ϫ1 suppressed 85% of urinary PGE 2 excretion, whereas at the dosage of 5 mg·kg Ϫ1 ·day Ϫ1 , 46% less PGE 2 was excreted (Fig. 4A) . The high dose of SC-236 affected glomerular diameter and cortical thickness in wild-type mice indis- Fig. 4, B and C) . Application of SC-236 at the lower dose of 5 mg·kg Ϫ1 ·day Ϫ1 also diminished glomerular size but to a lesser degree. A small but significant decrease in cortical thickness was detectable under this treatment, resembling the situation in COX-2 ϩ/Ϫ mice (Fig. 4, B and C) . Impairment of normal kidney development and function in COX-2 knockout mice is associated with an increase in renal fibrosis (29, 30) . To determine fibrotic alterations in COX-2 heterozygous mice, we used Sirius red staining to visualize fibrotic and sclerotic processes, such as collagen deposit periand intraglomerularily. A strong increase in staining of the glomerular tufts and Bowman's capsule was evident in COX-2 Ϫ/Ϫ mice (Fig. 5) . In kidney sections from COX-2 ϩ/Ϫ mice, we also observed an increase in intraglomerular staining (Fig. 5, A and B) ; however, Bowman's capsules were indifferent in staining to COX-2 ϩ/ϩ mice (Fig. 5, A and C) . To clarify the question of whether the observed morphological alterations in COX-2 ϩ/Ϫ mice translate into sustaining functional renal defects, we determined serum creatinine and urea used as surrogate parameters for kidney function in mice at the age of P90. Levels of serum creatinine (14.45 Ϯ 0.82 vs. 8.64 Ϯ 0.59 M, P Ͻ 0.005) and serum urea (26.45 Ϯ 1.28 vs. 8.34 Ϯ 0.38 mM, P Ͻ 0.001) were significantly higher in COX-2 Ϫ/Ϫ mice compared with COX-2 ϩ/ϩ mice. In COX-2 ϩ/Ϫ mice, we observed lower but significantly increased levels of creatinine (11.91 Ϯ 1.20 vs. 8.64 Ϯ 0.59 M, P Ͻ 0.05) but not of urea (Fig. 6, A and B) . In mice treated with SC-236, plasma creatinine concentration was increased but did not reach significance, whereas urea concentration was significantly higher compared with vehicle-treated control mice (15.05 Ϯ 1.31 vs. 8.27 Ϯ 0.45 mM, P Ͻ 0.0001; Fig. 6 , C and D) at the age of P90.
DISCUSSION
Genetic and functional loss of COX-2 causes impairment of late-phase postnatal kidney development (12, 27, 30) . Here, we report that loss of one copy of the COX-2 gene already hampers normal nephrogenesis and leads to a significant reduction in the diameter of glomeruli and slight thinning of the cortex. In addition, signs of intraglomerular fibrosis were seen in COX-2 ϩ/Ϫ mice. Although these damages in COX-2 ϩ/Ϫ kidneys are lesser compared with a complete knockout of the COX-2 gene, they still develop a significant reduction in renal function, albeit less severe than in COX-2-null mice. The morphological alterations seem to be directly linked to functional COX-2 expression in the critical timeframe between P4 and P8 after birth, as the amount of COX-2 mRNA and COX-2 protein are lower in COX-2 ϩ/Ϫ than in COX-2 ϩ/ϩ kidneys. Using a pharmacological approach, similar renal defects could be induced by different doses of the COX-2-selective inhibitor SC-236. Pharmacological suppression by the high dose of SC-236, causing suppression of PGE 2 excretion by ϳ80 -90%, results in defects similar to COX-2 Ϫ/Ϫ mice; inhibition by the low dose of SC-236, causing suppression of PGE 2 excretion by ϳ40 -50%, results in defects similar to COX-2 ϩ/Ϫ mice. Four conclusions can be drawn from these observations: first, a completely intact COX-2 system is needed for normal kidney development and kidney function. Second, a loss-offunction defect in one allele cannot be compensated by the other allele and already accounts not only for renal dysgenesis but also for diminished renal function. Third, in dependency of gene dosage, different issues of renal development are affected. Complete COX-2 deletion causes defects in glomeruli development and growth of cortical tissue; partial deletion mainly impairs glomerular but only marginally cortical maturation evident by only modest thinning of cortex corticis and an unchanged amount of superficial glomeruli. Finally, partial postnatal pharmacological inhibition of COX-2 activity in mice is already detrimental to kidney development and impairs nephrogenesis.
During metanephric formation, nephrons arise from pretubular aggregates that undergo a mesenchymal-to-epithelial Fig. 3 . Renal expression of COX-2, membrane-associated PGE synthase (mPGES)-1, and prostacyclin synthase (PGIS) in different COX-2 genotypes. Kidneys were harvested at P8 and used for RNA and protein analysis. Expression of mRNA for COX-2 (A), mPGES-1 (C), and PGIS (D) was determined by semiquantitative PCR. B: COX-2 protein expression was determined by ELISA relative to COX-2 ϩ/ϩ . E: PGE2 (left axis) and PGI2 (right axis) synthetic activity were studied using kidney homogenates incubated with arachidonic acid and calculated after liquid chromatography-tandem mass spectrometry analysis. For A-D, data represent means Ϯ SE of six independent experiments. *P Ͻ 0.05 by t-test. For E, data represent means Ϯ SE with n ϭ 6 -10 samples/group. *P Ͻ 0.05 compared with the COX-2 ϩ/ϩ group and #P Ͻ 0.05 compared with the COX-2 ϩ/Ϫ group by ANOVA all-group comparison.
transition to form renal vesicles at E12.5 and then proliferate to give rise to comma-and S-shaped bodies that fuse with the collecting duct epithelium (10) . Juxtamedullary glomeruli belonging to the oldest glomeruli developed shortly after E12.5. In COX-2 Ϫ/Ϫ as well as in COX-2 ϩ/Ϫ kidneys, these glomeruli exhibit a significantly smaller size compared with COX-2 ϩ/ϩ kidneys, indicating that growth and maturation of these prenatally formed glomeruli are also affected by diminished COX-2 activity. However, in contrast to the superficial and midcortical glomeruli, juxtamedullary glomeruli appear morphologically normal and functional. From our data, we conclude that COX-2-dependent prostanoids are involved not only in the development of superficial cortical new nephrons but also in the maturation of prenatally developed nephrons. A mere delay in kidney maturation in heterozygous mice can be excluded due to the elevated creatinine levels and presence of glomerulosclerosis at P90. Fig. 4 . Effect of the COX-2-selective inhibitor SC-236 on PGE2 excretion rate and kidney development. Adult wild-type C57BL6 mice were treated with SC-236 for 10 days, after which urine was collected and the urinary excretion rate was calculated (A). Data represent means Ϯ SE of samples from 8 mice. *P Ͻ 0.05 by ANOVA all-group comparison. Newborn pups from wild-type breeder pairs were treated with SC-236 at the indicated doses for the first 10 days after birth. At P21, kidneys were removed for analysis of glomerular size (B) and cortical thickness (C). Data represent means Ϯ SE of 3-5 mice. *P Ͻ 0.05 by ANOVA all-group comparison. In the early postnatal time course, renal COX activity alters and turns out to be transiently enhanced around P4 -P8 (15, 23) . Previously, we observed that these changes in activity are associated with temporary expression of COX-2 and mPGES-1, but not COX-1 or mPGES-2 or cytosolic PGE 2 synthase, and therefore concluded that the COX-2/mPGES-1/ PGE 2 axis is important for normal postnatal nephrogenesis and kidney maturation (15) . In 8-day-old COX-2 ϩ/Ϫ mice, renal COX-2 mRNA and protein expression are lowered by ϳ50% compared with age-matched COX-2 ϩ/ϩ mice. Furthermore, we observed a similar reduction in COX activity at the critical time point of P8, resulting in reduced formation of PGE 2 and 6-keto-PGF 1␣ , the hydrolyzation product of PGI 2 . Although COX-2 activity is hard to be determined without including COX-1 activity, we assume that the observed reduction in prostanoid synthesis is a consequence of diminished COX-2 expression and not of the secondary enzymes mPGES-1 and PGIS, as their mRNA expression was even higher in COX-2-deficient mice. This is further supported by the observation that the COX-2-selective inhibitor SC-236, in a dosage-dependent manner, causes similar depression in PGE 2 formation and similar damage to renal development. Whether the rise in mPGES-1 and PGIS expression mirrors some kind of feedback mechanism remains elusive. Clinically used COX-2 inhibitors, such as valdecoxib or etoricoxib, have also been shown to impair nephrogenesis (30) . In hypomorphic COX-2 Neo/Neo mice, COX-2 expression was reported to be reduced by ϳ70 -90%, however, these mice express only a mild renal phenotype as determined by a histopathological score system (32) . We observed severe renal damage in COX-2 Ϫ/Ϫ mice as well as in mice with ϳ90% pharmacologically suppressed COX-2 activity (the present study and Ref. 30) . One explanation for the difference from our study maybe that despite the strong reduction in COX-2 expression reported in Ref. 32 , the remaining COX activity is sufficient to supply necessary PGE 2 levels, as only a 50% reduction in 2,3-dinor-6-keto-PGF 1␣ , as an index for PGI 2 , but no reduction in metabolites of PGE 2 , used as an index for PGE 2 , was observed. Taking into account that mice deficient in PGE 2 receptor types EP2 or EP4 also show some degree of renal developmental impairment (15) , evidence is given for PGE 2 being crucial for COX-2-dependent nephrogenesis in mice (15, 30) . However, despite the observation that mice deficient in the PGI 2 receptor IP show no morphological or histological renal abnormalities (28), a renal developmental role for PGI 2 has still to be considered. On P8, we observed a reduced renal synthetic activity for PGI 2 next to PGE 2 in COX-2 Ϫ/Ϫ mice. Furthermore, kidneys of PGIS-deficient mice exhibit various renal abnormalities, such as atrophy, cysts, retraction of the renal cortex layer, and vascular injuries (36) . Some of these injuries are similar to those of COX-2 Ϫ/Ϫ mice; however, in general, the renal defects appear to be more severe. Fibrosis and necrosis lesions were observed from the renal medulla to the renal cortex, and mice with a small and undeveloped or even a missing kidney were also found (36) . Neither were observed in COX-2 Ϫ/Ϫ mice (12, 27) or in mice treated with COX-2-specific inhibitors (23, 30) .
In wild-type mice, the COX-2-selective inhibitors SC-236 and rofecoxib have been shown to provoke periglomerular fibrosis, a process that might contribute to renal insufficiency in the long term (30) . In COX-2 Ϫ/Ϫ mice aged 90 days, we detected a significant increase in Sirius red staining not only of the basement membranes of Bowman's capsules but also of glomerular tufts. In general, a significant part of Sirius red staining is considered as collagen type I and III deposition, a hallmark of fibrosis (14) . Minor fibrotic processes were also seen in the glomerular tuft of heterozygous mice but not in the basement membrane of Bowman's capsule. Whether the observed peri-and intraglomerular fibrotic alterations are also a consequence of missing prostanoids or due to impaired renal function needs to be elucidated. A possible candidate could be PGI 2 as PGIS deficiency results in the development of renal fibrosis (36) . Of interest, mice that overexpress COX-2 in podocytes exhibit normal renal development. However, these mice are predisposed to glomerular injury, e.g., by adriamycin, and exhibit albuminuria and foot process effacement (6) . COX-2 inhibition ameliorates albuminuria and retards progressive glomerulosclerosis in models of glomerular injury (7, 35) . Most feasible, prostanoids are acting in pro-and contrapathological processes depending on the differentiation status. Regarding nephrogenesis, an excess of PGE 2 formation seems not to interfere with normal development (6) .
Homozygous COX-2-null mice exhibit elevated blood urea nitrogen and creatinine in plasma or serum samples (2, 29) , indicating impaired renal function. This observation is in accordance with a reduced glomerular filtration rate, as measured by inulin clearance being reduced ϳ50% in mice lacking COX-2 (29) . In support, mice treated with COX-2-selective inhibitor also showed a significant increase in the retention marker of blood urea nitrogen. Heterozygous loss of COX-2 is sufficient to cause a significant increase in serum creatinine. Although blood urea nitrogen levels were similar to COX-2 ϩ/ϩ mice, this indicates that the renal pathological abnormalities seen in COX-2 ϩ/Ϫ mice already affect kidney function. It is unknown whether this renal insufficiency may precipitate in a rise in blood pressure in the long term. Based on a spherical structure of glomeruli, the observed size reduction in the COX-2 ϩ/Ϫ group will result in a diminishment to ϳ60% of normal glomerular volume. In the COX-2 Ϫ/Ϫ group, glomerular volume would be ϳ35% compared with a normally developed kidney. Several studies have indicated, at least for the number of glomeruli and thereby total glomerular volume, an inverse association with risk for hypertension (1, 26) .
Perspectives
Findings on basal blood pressure in COX-null mice are inconsistent (29, 32, 37) . In a recent study (3), we observed that homozygous COX-2-null mice exhibit significantly enhanced systolic and diastolic blood pressure compared with COX-2 ϩ/ϩ mice. Most interestingly, and in support of our present study, we also observed a significant rise in basal systolic blood pressure in heterozygote mice, albeit not as pronounced as in COX-2 Ϫ/Ϫ mice (3). It is unknown whether elevated blood pressure in these mice is a consequence of reduced COX-2-dependent vasodilatory prostanoid formation or of renal dysfunction. We speculate that polymorphisms that affect levels of COX-2 gene expression during gestation in the human population may result in subtle kidney damage, leading to some degree of kidney insufficiency (and possibly high blood pressure) in adults. Recent studies have suggested that single nucleotide polymorphisms in the COX-2 gene may alter enzyme function. The polymorphisms Ϫ765G¡C, Ϫ1195A¡G, and 8473T¡C in the COX-2 gene have been identified and proposed to be associated with cancer susceptibility, whereas a recent meta-analysis provided evidence only for the 1195A¡G polymorphism to be associated with an increased risk of digestive system cancers (13) . We are unaware of any polymorphisms associated with developmental defects or hypertension. Further studies are necessary to enlighten the role of COX-2 and nephrogenesis as a risk for renal insufficiency in humans.
Our results highlight a critical and dominant role of COX-2 in kidney development by demonstrating that heterozygous loss of COX-2 or partial pharmacological inhibition of postnatal COX-2 activity is sufficient to reduce glomerular volume and to induce sclerotic processes within the glomeruli, together most likely leading to reduced kidney function. In summary, full function of both COX-2 gene copies is necessary to achieve complete and normal development and maturation of the mouse kidney and to maintain normal renal excretory function.
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